SAMHSA Unveils $281 Million in MOUD Grants While Restricting Harm Reduction and Mandating Psychosocial Services
核心洞察
SAMHSA (搜索) announced $281.25 million across 15 federal grant programs, with $68.25 million dedicated to Medication-Assisted Treatment for opioid addiction supporting up to 91 recipients.
All grant applications must explicitly state they do not support harm reduction, with fentanyl test strips, clean needles, and overdose hotlines excluded from funding eligibility.
New guidance requires MOUD to be paired with psychosocial services and mandates annual clinician-patient discussions about discontinuing medication, raising concerns among providers.
On July 6, the Substance Abuse and Mental Health Services Administration (SAMHSA (搜索)) announced approximately $281.25 million in funding across 15 federal grant programs, with a substantial portion directed toward medications for opioid use disorder (搜索) (MOUD) and community overdose prevention. The funding, part of the Trump administration's Great American Recovery Initiative, comes with significant new restrictions that have sparked confusion and concern among healthcare providers and advocacy organizations.
The largest single investment—$68.25 million—will support the "Medication-Assisted Treatment – Prescription Drug and Opioid Addiction" grant, with SAMHSA (搜索) anticipating up to 91 recipients receiving approximately $750,000 each. Applications are due July 27, with pre-application webinars scheduled in the coming days.
New Restrictions on Harm Reduction
Each grant notice explicitly states that applications must "align with SAMHSA (搜索) Strategic Priorities and the application and budget narrative must not support harm reduction." The agency has redefined harm reduction as a model that promotes or enables drug use, while simultaneously reclassifying MOUD and naloxone access as issues unrelated to harm reduction.
Under the new guidance, SAMHSA (搜索) funding can no longer be used for clean needles or similar supplies; overdose hotlines whose primary function is providing a telephonic companion while someone is using drugs; sterile water, saline, or ascorbic acid "used to facilitate drug use"; or fentanyl test strips and similar kits for other drugs.
The limitation on fentanyl test strips has caused particular confusion, given that the 2026 National Drug Control Policy, released the week prior, declares that "Rapid test strips and similar technologies that detect fentanyl and other drugs are an important tool that should be legal and not considered drug paraphernalia."
"Pharmacists should not be prevented from providing access to harm-reduction tools that reduce the risk of overdose," said Tom Kraus, vice president of government relations for the American Society of Health-System Pharmacists (搜索) (ASHP). While the SAMHSA (搜索) policy does not prevent professionals from using test strips when caring for patients, ASHP expressed concern that limiting distribution for individual use will negatively impact overdose prevention efforts.
MOUD Requirements and Psychosocial Mandates
Recipients of the MAT grant must "ensure access" to methadone, either by providing it directly or through coordination with other programs, and ensure that "all applicable practitioners" complete the training necessary to prescribe buprenorphine. Recipients are required to offer at least one MOUD and must create "tobacco cessation programs" for people receiving MOUD, with the agency noting that integrating the two treatments "improves overall health outcomes without compromising OUD recovery."
A separate letter from SAMHSA (搜索) Principal Deputy Assistant Secretary Christopher Carroll urges providers to look at alternatives to medication in addiction treatment. "Research consistently demonstrates that individuals with opioid use disorder (搜索) have high rates of co-occurring substance use and mental illness, and there is growing recognition that medications alone cannot address the legal, housing, family functioning, and other challenges that people with substance use disorders commonly face," Carroll stated. "SAMHSA funding should be used to provide comprehensive treatment and recovery support services rather than medication-only models for opioid-use disorder."
The letter further stipulates that clinicians should have an annual discussion with patients about the possibility of discontinuing medication and that SAMHSA (搜索) funding should be used to train clinicians on options for safe tapering off. This language will be included in revised terms and conditions for current grantees and for future funding announcements.
Broader Context: Agency Restructuring and Mental Health Initiatives
The funding announcements follow a period of significant upheaval at SAMHSA (搜索). Of the 900 employees the agency had in January 2025, one-third had been let go by October 2025, and another 100 were summarily fired during the government shutdown, leaving the organization at half its starting staff. In January 2026, the administration announced nearly $2 billion in SAMHSA grant cuts, which were restored following 24 hours of confusion and outrage from lawmakers.
The administration's targeting of what it views as "overmedicalization" also extends to mental health treatment. HHS launched an initiative targeting overprescribing of psychiatric medications, with HHS Secretary Robert Kennedy Jr. stating, "We will no longer treat psychiatric medications as the default." During his confirmation hearing in February 2025, Kennedy told the Senate Finance Committee, "We are not just overmedicating our children, we are overmedicating our entire population."
In response, the American Federation for Suicide Prevention (搜索) cautioned, "Optimizing evidence-based care, with the goal of symptom remission and prevention of recurrence, saves lives. On the other hand, misinformation and fear of these treatments have led to decreased identification and treatment of depression, with serious public health consequences."
Additional Funding Allocations
Beyond the MAT grant, $34.7 million has been allocated for First Responders-Comprehensive Addiction and Recovery Act grants, which support naloxone and nalmefene trainings for first responders as well as local businesses and organizations viewed as "community anchors"—notably faith-based organizations, now that syringe service programs cannot apply for or be mentioned in these grants.
The grant notices also warn against applications supportive of Housing First or that "promote denial … of the sex binary in humans, or the belief that sex is a chosen or mutable characteristic."
Great American Recovery Initiative Co-Chair Kathryn Burgum articulated the administration's framework at the Oval Office launch in January: "Addiction is not a moral failure. It is not a character flaw. And it's not simply a behavioral issue. Addiction is a lifelong, chronic, relapsing medical disease—as real as diabetes, cancer and heart disease." Yet critics note that while the administration frames addiction as a medical disease, it simultaneously mandates that MOUD be provided with psychosocial services—a requirement not typically applied to the medical treatment of diabetes, cancer, or heart disease.